Brief: Cantargia Completes Patient Recruitment To Phase IIa Pancreatic Cancer Extension Cohort In CANFOUR Study
10/09/2021 12:32
Sept 10 (Reuters) - Cantargia AB CANTA.ST :
* CANTARGIA AB - (R) CANTARGIA COMPLETES PATIENT RECRUITMENT
TO
PHASE IIA PANCREATIC CANCER EXTENSION COHORT IN CANFOUR STUDY
* PRELIMINARY DATA FROM THESE PATIENTS CONFIRM A GOOD SAFETY
PROFILE OF NADUNOLIMAB (CAN04) COMBINED WITH
GEMCITABINE/NAB-PACLITAXEL
* PRESENTATION OF SAFETY AND EFFICACY DATA FOR EXTENSION
COHORT IS
PLANNED FOR FIRST HALF OF 2022
Source text for Eikon: ID:nNDL8cy6g9
Further company coverage: CANTA.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 769 6600;))
Recent news on Cantargia AB
See all newsBrief: Cantargia Publishes Nadunolimab CANFOUR Study Data
Brief: Cantargia Announces Outcome Of Rights Issue, Raising About SEK 75 Mln
Brief: Cantargia Carries Out Rights Issue, Enters Loan Agreement
Brief: Cantargia Q1 Operating Loss Narrows To SEK 36.9 Mln
Brief: Cantargia: Early Results From Phase 1B/2A Nadunolimab Trial In MDS And AML